NRX Pharmaceuticals, Inc. Interest Income (Expense), Net
NRX Pharmaceuticals, Inc. (NRXP) reported Interest Income (Expense), Net of $88 for the 3-month period ending 2021-03-31, per its 10-Q filed 2021-05-21.
Discontinued › Income Statement › Other Income
us-gaap:InterestIncomeExpenseNet · last filed 2021-05-21
- NRX Pharmaceuticals, Inc. interest income (expense), net for the quarter ending 2021-03-31 was $88.00, a 99.92% decline year-over-year.
- NRX Pharmaceuticals, Inc. interest income (expense), net for the quarter ending 2020-12-31 was $111.00, a 99.94% decline year-over-year.
- NRX Pharmaceuticals, Inc. interest income (expense), net for the quarter ending 2020-09-30 was $559.00, a 99.78% decline year-over-year.
- NRX Pharmaceuticals, Inc. interest income (expense), net for the quarter ending 2020-06-30 was $25.02K, a 93.63% decline year-over-year.
- NRX Pharmaceuticals, Inc. interest income (expense), net for fiscal 2020 was $138.76K, a 88.49% decline from fiscal 2019.
- NRX Pharmaceuticals, Inc. interest income (expense), net for fiscal 2019 was $1.21M, a 10.74% increase from fiscal 2018.
- NRX Pharmaceuticals, Inc. interest income (expense), net for fiscal 2018 was $1.09M.
| Period end | Interest Income (Expense), Net 3 month | Interest Income (Expense), Net 6 month | Interest Income (Expense), Net 9 month | Interest Income (Expense), Net 12 month |
|---|---|---|---|---|
| 2021-03-31 | $88.00 10-Q · filed 2021-05-21 | $199.00 derived: sum of 2 quarters · filed 2021-05-21 | $758.00 derived: sum of 3 quarters · filed 2021-05-21 | $25.77K derived: sum of 4 quarters · filed 2021-05-21 |
| 2020-12-31 | $111.00 derived: 10-K/A 12 month − 10-Q 9 month · filed 2021-05-14 | $670.00 derived: sum of 2 quarters · filed 2021-05-14 | $25.69K derived: sum of 3 quarters · filed 2021-05-14 | $138.76K 10-K/A · filed 2021-05-14 |
| 2020-09-30 | $559.00 10-Q · filed 2020-11-16 | $25.58K derived: sum of 2 quarters · filed 2020-11-16 | $138.65K 10-Q · filed 2020-11-16 | $310.94K derived: sum of 4 quarters · filed 2021-05-21 |
| 2020-06-30 | $25.02K 10-Q · filed 2020-08-14 | $138.09K 10-Q · filed 2020-08-14 | $310.38K derived: sum of 3 quarters · filed 2021-05-21 | $568.61K derived: sum of 4 quarters · filed 2021-05-21 |
| 2020-03-31 | $113.08K 10-Q · filed 2021-05-21 | $285.36K derived: sum of 2 quarters · filed 2021-05-21 | $543.60K derived: sum of 3 quarters · filed 2021-05-21 | $936.03K derived: sum of 4 quarters · filed 2021-05-21 |
| 2019-12-31 | $172.28K derived: 10-K/A 12 month − 10-Q 9 month · filed 2021-05-14 | $430.52K derived: sum of 2 quarters · filed 2021-05-14 | $822.96K derived: sum of 3 quarters · filed 2021-05-14 | $1.21M 10-K/A · filed 2021-05-14 |
| 2019-09-30 | $258.24K 10-Q · filed 2020-11-16 | $650.67K derived: sum of 2 quarters · filed 2020-11-16 | $1.03M 10-Q · filed 2020-11-16 | $1.35M derived: sum of 4 quarters · filed 2020-11-16 |
| 2019-06-30 | $392.44K 10-Q · filed 2020-08-14 | $775.30K 10-Q · filed 2020-08-14 | $1.09M derived: sum of 3 quarters · filed 2020-08-14 | $1.38M derived: sum of 4 quarters · filed 2020-08-14 |
| 2019-03-31 | $382.86K 10-Q · filed 2020-05-15 | $702.34K derived: sum of 2 quarters · filed 2020-05-15 | $985.73K derived: sum of 3 quarters · filed 2020-05-15 | $1.26M derived: sum of 4 quarters · filed 2020-05-15 |
| 2018-12-31 | $319.47K derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-30 | $602.86K derived: sum of 2 quarters · filed 2020-03-30 | $875.35K derived: sum of 3 quarters · filed 2020-03-30 | $1.09M 10-K · filed 2020-03-30 |
| 2018-09-30 | $283.39K 10-Q · filed 2019-11-14 | $555.87K derived: sum of 2 quarters · filed 2019-11-14 | $769.44K 10-Q · filed 2019-11-14 | $0.00 10-Q · filed 2018-11-08 |
| 2018-06-30 | $272.48K 10-Q · filed 2019-08-14 | $486.05K 10-Q · filed 2019-08-14 | $520.23K derived: sum of 3 quarters · filed 2019-08-14 | |
| 2018-03-31 | $213.57K 10-Q · filed 2019-05-15 | $247.75K derived: sum of 2 quarters · filed 2019-05-15 | ||
| 2017-12-31 | $34.18K 10-K · filed 2019-03-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MEDICINOVA INC (MNOV) | United States | $0.130B | -6.04 |
| Unicycive Therapeutics, Inc. (UNCY) | United States | $0.134B | -3.70 |
| TuHURA Biosciences, Inc./NV (HURA) | United States | $0.134B | -4.88 |
| IMMUNIC, INC. (IMUX) | United States | $0.127B | -1.88 |
| INOVIO PHARMACEUTICALS, INC. (INO) | United States | $0.125B | -1.35 |
| Curanex Pharmaceuticals Inc (CURX) | United States | $0.138B | |
| Atrium Therapeutics, Inc. (RNA) | United States | $0.140B | |
| Aardvark Therapeutics, Inc. (AARD) | United States | $0.121B | -1.80 |
| Korro Bio, Inc. (KRRO) | United States | $0.141B | -1.81 |
| CUMBERLAND PHARMACEUTICALS INC (CPIX) | United States | $0.121B | -8.95 |